35th week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130224084 | OZONE GENERATING DEVICE - An ozone generating device includes three or more cooling channels each having a through-hole formed in a central region thereof and a coolant flow path formed therein. The cooling channels are arranged side by side such that the through-holes thereof overlap with one another. The ozone generating device further includes electric discharge units interposed between the cooling channels adjoining each other and configured to generate electric discharge when applied with a high voltage. Each of the electric discharge units has a central hole formed in alignment with the through-hole. The ozone generating device is configured such that, when the electric discharge units are applied with a high voltage with the cooling channels kept grounded, oxygen supplied to the electric discharge units is decomposed into ozone which in turn is discharged through an internal space defined by the through-hole and the central hole. | 2013-08-29 |
20130224085 | SPORTS EQUIPMENT SANITIZER - An apparatus for removing mold and mildew from sports equipment includes an ozone generator that supplies ozone to a distribution system that directs ozone at a high velocity to both dry and sanitize sports equipment. The high velocity flow of ozone is directed to the interior portions of the sports equipment to dry and sanitize the equipment. The high speed flow of the ozone provides for drying of the interior surfaces of the equipment while also direction impinging ozone flow on interior surfaces to remove undesirable mold and mildew. | 2013-08-29 |
20130224086 | Germicidal Systems and Apparatuses having Hollow Tumbling Chambers - Systems are provided which include a disinfection apparatus, a hollow chamber comprising an object entry port, and a means for tumbling objects placed inside the chamber. In some cases, the hollow chamber is configured such that a germicide projected from the disinfection apparatus is transmitted into an interior cavity of the chamber. In other cases, the hollow chamber may include an input port configured for coupling the chamber to the disinfection apparatus such that a germicide generated by the disinfection apparatus is transmitted into the hollow chamber via the input port when the chamber is coupled to the disinfection apparatus. In other cases, the disinfection apparatus may be disposed within the hollow chamber and configured to generate a germicide in the form of a plasma, ultraviolet light, a non-aqueous vapor, a non-aqueous liquid or a gas which is molecularly configured to deactivate or kill microorganisms. | 2013-08-29 |
20130224087 | Manual Dosing Device - A manual dosing device comprising
| 2013-08-29 |
20130224088 | HISTOLOGICAL SPECIMEN CASSETTE - A unitary molded polymer histological specimen cassette includes a base defining a compartment, a lid, and a hinge connecting the lid to the base and enabling the lid to move between an open position and a closed position with respect to en the base. The lid and base are configured to form a fulcrum and apply sufficient tension to the hinge to fracture the hinge when the lid is moved from the open position to the closed position. Another embodiment of the cassette includes a panel extending from the base and having a print-receptive front surface, a rear surface and a first thickness. A plurality of spaced apart support walls extend between and are integrally molded with the base and the rear surface of the panel to support the panel with respect to the base. The cassette includes a sufficient number of support walls at spaced-apart positions to provide the panel with sufficient rigidity to enable printing on the print-receptive surface. All of the support walls have a substantially equal second thickness that is less than the first thickness of the panel, and the second thickness is a thickness with respect to the first thickness that causes the panel to be sufficiently flat and smooth to enable printing on the print-receptive surface. | 2013-08-29 |
20130224089 | MIXING APPARATUS - A mixing apparatus includes: a mixing container with a discharge port for discharging mixed liquid; a filter paper covering the discharge port to temporarily retain the liquid; a receiving unit with a waste liquid collecting portion for receiving a first liquid discharged from the discharge port through the filter paper, and a measuring portion for receiving a second liquid subjected to treatment different from treatment for the first liquid; and an operation portion for enabling selection between a first receiving state in which the waste liquid collecting portion receives the first liquid and a second receiving state in which the measuring portion receives the second liquid, and also for controlling the movement of the first liquid or the second liquid. | 2013-08-29 |
20130224090 | CATALYST FOR SELECTIVE OXIDATION OF NH3 TO N2 AND METHOD FOR PREPARING THE SAME - Disclosed is a catalyst which can convert ammonia contained in exhaust gas from an engine of a vehicle equipped with a Urea-SCR (Urea-Selective Catalytic Reduction) system, to nitrogen, and a method for preparating the same. The catalyst can convert ammonia which is failed to participate in a conversion reaction of NOx to N2 and slipped out of the SCR catalyst, to nitrogen via a SCO (Selective Catalytic Oxidation) reaction, before the ammonia is released to the air. | 2013-08-29 |
20130224091 | Low Pressure Drop Extruded Catalyst Filter - A batch composition for making a highly porous honeycomb ceramic catalytic filter article, including base inorganic components including a mixture of a nano-zeolite powder, and an inorganic filler, in amounts defined herein; and super additives including: a mixture of at least two pore formers; a binder; and a metal salt, in amounts defined herein. Also disclosed are extruded catalyst filter articles and methods for making the articles. | 2013-08-29 |
20130224092 | INHIBITING CORROSION CAUSED BY AQUEOUS ALDEHYDE SOLUTIONS - Aldehydes useful as H | 2013-08-29 |
20130224093 | PROCESS AND APPARATUS FOR REMOVAL OF NITROGEN OXIDES, SULFUR OXIDES AND MERCURY FROM OFF GAS THROUGH OXIDIZATION - Provided is a process for integrating treatment of off gas through NO | 2013-08-29 |
20130224094 | AMMONIA DESTRUCTION METHODS FOR USE IN A CLAUS TAIL GAS TREATING UNIT - Oxidative and reductive methods are described for the cost-effective destruction of an ammonia-bearing gas stream, potentially containing minor but significant quantities of hydrogen sulfide (H | 2013-08-29 |
20130224095 | PROCESS OF REMOVING NOx FROM FLUE GAS - The invention includes a process for reducing the amount of NO | 2013-08-29 |
20130224096 | PHOTOCATALYST COATED BODY AND PHOTOCATALYST COATING LIQUID - A photocatalyst coated body includes a base and a photocatalyst layer provided on the base. The photocatalyst coated body is characterized in that photocatalyst layer contains 1-20 (inclusive) parts by mass of photocatalyst particles, 30-98 (inclusive) parts by mass of silica particles and 1-50 (inclusive) parts by mass of zirconia particles, so that the total all of these particles is 100 parts by mass. The photocatalyst coated body is also characterized in that the zirconia particles are at least one kind of particles selected from the group consisting of crystalline zirconia particles having an average crystallite diameter of 10 nm or less and amorphous zirconia particles. Such photocatalyst coated body has excellent photocatalytic degradation function and excellent weather resistance; and also it is capable of suppressing the formation of intermediate products such as NO | 2013-08-29 |
20130224097 | APPARATUS AND METHOD FOR THE PRODUCTION OF TRISILYAMINE - There is described an apparatus, a tubular laminar flow, plug flow reactor, for making silylamines and particularly trisilylamine (TSA) in high yields from ammonia gas and a monohalosilane gas. The apparatus can be a tubular flow reactor comprising a first portion of the reactor defining a gas entry zone, a second portion of the reactor defining a reaction zone and a third portion of the reactor defining a separation zone, the reaction zone providing a reactant contacting region. Trisilylamine can be recovered in the separation zone in a cold trap collection vessel. | 2013-08-29 |
20130224098 | USE OF A REACTOR WITH INTEGRATED HEAT EXCHANGER IN A PROCESS FOR HYDRODECHLORINATING SILICON TETRACHLORIDE - The invention relates to a method for converting silicon tetrachloride by means of hydrogen to form trichlorosilane in a modified hydrodechlorination reactor. The invention further relates to a the use of such a modified hydrodechlorination reactor as an integrated component of a system for producing trichlorosilane from metallurgical silicon. | 2013-08-29 |
20130224099 | METHODS FOR REACTING COMPOUNDS - Shell and tube heat exchangers that include a baffle arrangement that improves the temperature profile and flow pattern throughout the exchanger and/or that are integral with a reaction vessel are disclosed. Methods for using the exchangers including methods that involve use of the exchanger and a reaction vessel to produce a reaction product gas containing trichlorosilane are also disclosed. | 2013-08-29 |
20130224100 | ELECTROMAGNETIC MIXING FOR NITRIDE CRYSTAL GROWTH - A method and apparatus for bulk Group-III nitride crystal growth through inductive stirring in a sodium flux growth technique. A helical electromagnetic coil is closely wound around a non-conducting cylindrical crucible containing a conductive crystal growth solution, including both precursor gallium and sodium, wherein a nitrogen-containing atmosphere can be maintained at any pressure. A seed crystal is introduced with the crystal's growth interface submerged slightly below the solution's surface. Electrical contact is made to the coil and an AC electrical field is applied at a specified frequency, in order to create eddy currents within the conductive crystal growth solution, resulting in a steady-state flux of solution impinging on the submerged crystal's growth interface. | 2013-08-29 |
20130224101 | RAW MATERIAL CARBON COMPOSITION FOR NEGATIVE ELECTRODE MATERIAL OF LITHIUM-ION SECONDARY BATTERY - Provided is a raw material carbon composition for a negative electrode material for a lithium-ion secondary battery useful for achieving excellent high-speed charge and discharge characteristics. The raw material carbon composition is obtained by subjecting a stock oil composition to coking treatment, the stock oil composition being obtained by blending a stock oil (1) having a density at 15° C. of from 0.96 to 1.05 g/cm | 2013-08-29 |
20130224102 | PROCESS FOR UTILIZING A WATER STREAM IN A HYDROLYSIS REACTION TO FORM ETHANOL - In one embodiment, the invention is to a process for producing a water stream comprising the steps of hydrogenating acetic acid to form a crude ethanol product and separating at least a portion of the crude ethanol product in at least one column of a plurality of columns into a distillate comprising ethanol and a residue comprising the water stream. The water stream preferably is essentially free of organic impurities other than acetic acid and ethanol. | 2013-08-29 |
20130224103 | SYSTEM FOR CALCINING ACTIVE LIME WITH A PRECALCINING FURNACE AND METHOD USING THE SAME - The invention provides a system for calcining active lime, including a precalcining furnace for receiving limestone materials to be calcined and precalcining the limestone materials, and a rotary kiln for receiving the materials containing precalcined product from the precalcining furnace, outputting the formed active lime, and at the same time supplying a first flue gas to the precalcining furnace. The calcining system further includes a precalcining furnace combustion device, which generates a second flue gas and supplies it to the precalcining furnace, such that the limestone materials are precalcined in the precalcining furnace under the action of the first flue gas and the second flue gas. In this way, the precalcining rate of the limestone materials in the precalcining furnace is significantly improved. Since the heat exchange in the precalcining furnace is mainly in the form of convective heat exchange having a high heat efficiency, the heat exchange efficiency of the whole system is improved, and thus the heat consumption of the system is reduced. | 2013-08-29 |
20130224104 | Heat Exchanger Using Non-Pure Water for Steam Generation - A process and a device are described for producing high purity and high temperature steam from non-pure water which may be used in a variety of industrial processes that involve high temperature heat applications. The process and device may be used with technologies that generate steam using a variety of heat sources, such as, for example industrial furnaces, petrochemical plants, and emissions from incinerators. Of particular interest is the application in a thermochemical hydrogen production cycle such as the Cu—Cl Cycle. Non-pure water is used as the feedstock in the thermochemical hydrogen production cycle, with no need to adopt additional and conventional water pre-treatment and purification processes. The non-pure water may be selected from brackish water, saline water, seawater, used water, effluent treated water, tailings water, and other forms of water that is generally believed to be unusable as a direct feedstock of industrial processes. The direct usage of this water can significantly reduce water supply costs. | 2013-08-29 |
20130224105 | SEMICONDUCTOR PHOTOCATALYST FOR THE PHOTOCATALYTIC REFORMING OF BIOMASS DERIVATIVES FOR HYDROGEN GENERATION, AND PREPARATION AND USE THEREOF - Disclosed are a semiconductor photocatalyst for the photocatalytic reforming of biomass derivatives for hydrogen generation, and preparation and use thereof. The semiconductor photocatalyst has the atomic composition ratio of M˜N-Ax; wherein M˜N are IIB group elements to VIA group elements, or IIIA group elements to VA group elements, A being one element or more than two elements selected from the group consisting of cobalt, nickel, iron, copper, chromium, palladium, platinum, ruthenium, rhodium, iridium and silver; and 0.02%≦x≦1.0%. The method of in-situ preparation of the highly effective semiconductor photocatalyst and catalytically reforming biomass derivatives for hydrogen generation by driving photoreaction with visible light via quantum dots is simple, fast, highly effective, inexpensive and practical. The in situ reaction can occur in sunlight without the need of harsh conditions such as calcination. | 2013-08-29 |
20130224106 | HYDROGEN GENERATION - A process for the decomposition of methane can be controlled to form ethane or hydrogen with a solid carbon product. | 2013-08-29 |
20130224107 | HETEROCYCLIC DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF - Disclosed are heterocyclic derivatives, methods for making them, compositions containing the same and uses thereof. Particularly, their pharmaceutical use as inhibitors of PARP is disclosed. | 2013-08-29 |
20130224108 | Methods for the Treatment of Head and Neck Squamous Cell Carcinoma - This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof. | 2013-08-29 |
20130224109 | COMPOSITIONS AND METHODS FEATURING IL-6 AND IL-21 ANTAGONISTS - The present invention features compositions for inhibiting both the IL-6 and the IL-21 pathways and methods of making and using such compositions. Our work to date indicates the importance of the redundancy of IL-6 and IL-21 to perform certain crucial functions. The pathways can be inhibited by inhibiting the ligands (i.e., IL-6 and IL-21) and/or their respective receptors (i.e., the IL-6 receptor and IL-21 receptor). Alternatively, or in addition, upstream and downstream effectors in the IL-6 and IL-21 pathways can be blocked. The agents used can be antibody or antibody-based proteins or peptides including circulating receptors, optionally coupled to an immunoglobulin or a portion thereof (e.g., the Fc region). Also provided are methods for using the compositions, for example, in organ transplantation, tissue grafting, or autoimmune disorders. | 2013-08-29 |
20130224110 | USE OF ADENOSINE RECEPTOR SIGNALING TO MODULATE PERMEABILITY OF BLOOD-BRAIN BARRIER - The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed. | 2013-08-29 |
20130224111 | Inhibition Of CD69 For Treatment Of Inflammatory Conditions - A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical. | 2013-08-29 |
20130224112 | COMPOSITIONS AND METHODS FOR SURFACE ABRASION WITH FROZEN PARTICLES - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2013-08-29 |
20130224113 | IMAGING DIAGNOSTICS BY COMBINING CONTRAST AGENTS - The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation. | 2013-08-29 |
20130224114 | Translocator Protein Ligands - The present invention relates to compounds and methods for imaging translocator protein (18 kDa) (TSPO) expression in a subject. This invention also relates to compounds and methods for the treatment of neurodegenerative disorders, inflammation or anxiety in a subject. | 2013-08-29 |
20130224115 | NON-RADIOACTIVE AGENTS FOR NEUROBLASTOMA IMAGING - Multi-modal tumor imaging of neuroblastoma is essential for tumor staging, response evaluation and detection of relapsed diseased. The present invention provides a norepinephine analogue with a near-infrared (near-IR) dye, W765-BG, that efficiently and stably detects neuroblastoma in vivo using near-IR optical imaging. Confocal microscopy and optical imaging of neuroblastoma xenografts shows cell specific uptake and reveals exceptional tumor retention with a high tumor-to-tissue ratio up to 7 days after injection of W765-BG. | 2013-08-29 |
20130224116 | Markers of Endothelial Progenitor Cells and Uses Thereof - The present invention provides markers of endothelial progenitor cells (EPCs) and use of those markers and reagents that bind thereto to detect EPC cells or diagnose, prognose, treat or prevent EPC-associated conditions. | 2013-08-29 |
20130224117 | LATENT VARIABLE APPROACH TO THE IDENTIFICATION AND/OR DIAGNOSIS OF COGNITIVE DISORDERS AND/OR BEHAVIORS AND THEIR ENDOPHENOTYPES - Certain embodiments are directed to methods of distinguish “target-relevant” variance in observed clinical and physiological measures from the variance in observed data that is unrelated to any target process. | 2013-08-29 |
20130224118 | PERHEXILINE FOR TREATING CHRONIC HEART FAILURE - Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin. | 2013-08-29 |
20130224119 | OMENTUM AND USE THEREOF - In some embodiments, mammalian omentum and methods of using the same for treating symptoms and/or conditions related to dementia are provided. In addition, a composition comprising the omentum tissue and/or the extract thereof is described in some embodiments. In some other embodiments, methods of formulating and administering the composition are also provided. In addition, a cultured cell system to culture cells and/or tissues of the omentum is described. Some aspects of embodiments provide methods of identifying one or more biological agent from the omentum tissue. In another aspect of the embodiments, methods of testing the effect of stimulation omentum in treating dementia conditions are described. | 2013-08-29 |
20130224120 | MULTIMODAL DIAGNOSTIC TECHNOLOGY FOR EARLY STAGE CANCER LESIONS - Disclosed herein are compositions of a multimodal detection agent and methods of fabricating the same. The multimodal detection agent comprises a plurality of metallic nanoparticles attached to a surface of a polymeric carrier. The detection agent further comprising one or more target-specific binding agents attached to the metallic nanoparticles or the polymeric carrier. | 2013-08-29 |
20130224121 | PARTICLE CONTAINING HYDROPHOBIC DYE HAVING CYANINE STRUCTURE, AND CONTRAST AGENT CONTAINING THE PARTICLE - Provided is a particle which can stably hold a dye in itself even in an aqueous solution such as serum, in order to solve such a problem of a particle containing ICG, which has been conventionally used in a contrast agent or the like, that the ICG is a dye having a hydrophilic functional group and hence the ICG leaks out of the particle in an aqueous solution such as serum. More specifically, provided is a particle including a hydrophobic dye having a cyanine structure, in which the hydrophobic dye is represented by the following chemical formula (1). | 2013-08-29 |
20130224122 | MAGNETOTATIC BACTERIA MRI POSITIVE CONTRACT ENHANCEMENT AGENT AND METHODS OF USE - Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. | 2013-08-29 |
20130224123 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER - The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions. | 2013-08-29 |
20130224124 | Liquid non-stick toothpaste - My tooth cream will not stick, this is what makes it different from other tooth pastes. It can be dispensed in any type container, but it is different in that this toothpaste contains NO thickeners, no carrageenan, no cellulose gum, no glycerin and no SLS (sodium lanyl sulfates). My tooth créme can contain colorings, flavorings, preservatives, xylitol, sweetenings, fluoride . . . infinity. | 2013-08-29 |
20130224125 | ALCOHOL-FREE SLIGHTLY-ALCOHOLIC ORAL CARE COMPOSITION AND A PROCESS FOR PREPARING SAME - An aqueous, heat and cold stable, non-alcoholic or slightly-alcoholic microemulsion based antimicrobial mouthwash composition with improved antimicrobial efficacy. The composition comprises a unique water-soluble matrix composite, at least one water-immiscible or water-insoluble antimicrobial agent, and optionally, a preservative or preservative system, a weak carboxylic acid, a coloring agent and other additives. Examples of antimicrobial agents include menthol, thymol, eucalyptol and/or methyl salicylate. A process for preparing the oral care composition is also disclosed. | 2013-08-29 |
20130224126 | Oral Care Product and Methods of Use and Manufacture Thereof - This invention relates to a mouthwash comprising an aqueous solution of an effective amount of a basic amino acid, in free or salt form together with an effective amount of a preservative selected from methylisothiazolinone (MIT), benzyl alcohol, phenoxyethanol, and combinations thereof; as well as to methods of using and of making such compositions. | 2013-08-29 |
20130224127 | COMPOSITIONS AND RELATED METHODS FOR ORAL WELLNESS - The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein. | 2013-08-29 |
20130224128 | DENTAL CLEANSER COMPOSITION FOR IMPROVING ADHESION TO TEETH - The present invention relates to a dental cleanser composition for improving adhesion to teeth, and more particularly to, a dental cleanser composition which functions to remove not only a smear layer from the dentin surface of an exposed tooth root, but also oral bacteria, and thus is effective in improving adhesion to teeth in periodontal surgery. The present invention provides a dental cleanser composition containing sodium ethylene diaminotetraacetate and octyl phenol ethoxylate which is a surfactant. Sodium ethylene diaminotetraacetate in the composition functions to remove a smear layer on the tooth root surface and has antibacterial activity, and octyl phenol ethoxylate in the composition functions to lipopolysaccharide. Thus, the composition improves adhesion to teeth in periodontal surgery. | 2013-08-29 |
20130224129 | Compositions and Related Methods for Oral Wellness - Disclosed are compositions, apparatus, and related methods and systems for oral health care. | 2013-08-29 |
20130224130 | COSMETIC COMPOSITION FOR LONG-WEARING PROPERTIES - Disclosed are cosmetic compositions comprising (1) at least one MQTPr siloxane resin; (2) at least one film former chosen from a silicone acrylate copolymer; (3) at least one film former chosen from a hydrogenated hydrocarbon copolymer; (4) at least one fatty phase; and (5) optionally at least one wax and/or colorant. Also disclosed are methods for improving at least one property of a cosmetic composition, and methods for making up and/or enhancing the appearance of keratinous substrates using compositions according to the invention. | 2013-08-29 |
20130224131 | 4-AMIDINO BENZYLAMINES FOR COSMETIC AND/OR DERMATOLOGICAL USE - This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the epidermal barrier. Barrier abnormalities and disruptions respectively are often the starting point of a dry skin state, of itching, of dandruff and of the perception of sensitive skin. These 4-amidino benzylamine derivatives can be used for topical skin and scalp care applications in form of creams, lotions, gels, shampoos and the like. | 2013-08-29 |
20130224132 | COLOURING PRE-MIX FOR USE IN COLOURING OF A COSMETIC COMPOSITION - The present invention provides a colouring pre-mix for use in colouring of a cosmetic composition and a coloured cosmetic composition including the same, wherein the colouring pre-mix includes 45-80 wt-% benzyl benzoate; 20-49 wt-% dipropylene glycol; 0.00001-5 wt-% colouring plant extracts; and optionally 0.00001-5 wt-% colorants; with the provision that the content of benzyl benzoate exceeds the content of dipropylene glycol, wherein all data given in wt-% refer to the total weight of the colouring pre-mix. | 2013-08-29 |
20130224133 | SURFACTANT-FREE OIL-IN-WATER TYPE EMULSION, PROCESS FOR PREPARATION THEREOF AND ITS USES - There is described an oil-in-water emulsion free of surfactant agents comprising: A) At least a cross-polymer acrylate/alkyl-acrylate or derivatives thereof, or mixtures thereof in the aqueous phase of the emulsion; b) At least a polyacrylate or derivatives thereof, or mixtures thereof in the oily phase of the emulsion, and c) At least a neutralizing agent. Further, the present invention refers to a process of obtaining a surfactant-free emulsion and its use in cosmetics and pharmaceuticals compositions. The emulsion in question can be applied to all kinds of skin, being also indicated for people with sensitive skin. | 2013-08-29 |
20130224134 | NITROCELLULOSE-FREE NAIL POLISH COMPOSITIONS - The present invention relates to a nail polish composition comprising: at least one high gloss film forming agent chosen from a styrene maleic anhydride copolymer; at least one co-film forming agent chosen from an epoxy resin; at least one reactive agent chosen from a combination of a polyalkyleneamine and a polyurethane, at least one polyalkyleneamine, and at least one alkoxysilane comprising at least one solubilizing functional group; at least one solvent chosen from at least one volatile solvent and water; optionally, at least one plasticizer; and optionally, at least one colorant, wherein the composition does not require use of nitrocellulose and can be used to makeup or protect nails. | 2013-08-29 |
20130224135 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES - The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier. | 2013-08-29 |
20130224136 | CHIRAL COMPOUNDS, COMPOSITIONS, PRODUCTS AND METHODS EMPLOYING SAME - Compounds that function, alone or in combination, as inhibitors of pigmentation for the improvement of mammalian skin are described herein. Specifically, the compounds of the present disclosure, namely chiral, non-racemic compounds, function as pigment formation inhibitors thereof to beautify skin and discourage the production of melanins. One or more products, consumer and otherwise, comprising the chiral, non-racemic compounds are disclosed herein. Methods of employing both the compounds of the present disclosure and the products incorporating the present compounds are also disclosed herein. | 2013-08-29 |
20130224137 | SKIN LIGHTENING COMPOSITIONS - Compositions and methods for lightening mammalian skin are described herein. | 2013-08-29 |
20130224138 | LANOLIN SUBSTITUTE, PRODUCTION METHOD THEREOF AND APPLICATIONS OF SAME - This invention proposes a lanolin substitute, capable of absorbing up to at least twice its weight of water or aqueous solution or aqueous suspension. It forms true emulsions, stable over time with a capacity for water absorption superior to that of lanolin. | 2013-08-29 |
20130224139 | Bisurea Gelling Agents and Compositions - Bisurea gelling agents that impart a number of unexpected benefits within various gelled formulations and exhibit great versatility in terms of gelling capabilities for many types of solvents are provided. Such gelling agents should include pendant groups, such as sterically hindering alkyl groups attached to polyoxyalkylenated moieties that allow the gelling agent to be compatible with the target liquid system at elevated temperatures, while controlling and/or limiting the network formation and strength during the cooling cycle. Alternatively, novel gelling agents having two urea groups but that are asymmetrical in configuration have been produced in order to provide the same control in temperature, compatibility, and efficiency. Final gelled formulations, such as antiperspirant sticks and other like consumer items, are provided as well within this invention. | 2013-08-29 |
20130224140 | Aluminum Salt Containing High Percentage of Al30 - A composition comprising an aluminum chlorohydrate salt, the aluminum chlorohydrate salt having at least 50 mole % Al | 2013-08-29 |
20130224141 | METHOD FOR STRAIGHTENING HAIR - A method of straightening hair comprising the step of applying to the hair a composition comprising at least 2 wt % of the total composition of vitamin C and vitamin E. | 2013-08-29 |
20130224142 | MASCARA COMPOSITIONS CONTAINING A MICRONIZED WAX AND A NONIONIC POLYCONDENSATE - The invention relates to a composition comprising at least one nonionic polycondensate and at least one micronized wax which, if desired, can be processed at room temperature. | 2013-08-29 |
20130224143 | HAIR CONDITIONING COMPOSITION - The present invention is a hair conditioning composition includes approximately 40,000 IU of Vitamin E oil from 2 fl. oz., approximately 2 fl. oz. of 100% pure Australian tea tree oil, approximately 4 fl. oz. of Jojoba oil, approximately 32 oz. of pure extra virgin organic coconut oil with 62 percent MCT's and approximately 4 fl. oz. of 100 percent cold pressed sweet almond oil. The hair conditioning composition also includes approximately 4 fl. oz. of 100 percent pure Vitamin E, approximately 16 fl. oz. of cold pressed paraben free hexane free castor oil, approximately 16 fl. oz. of 100 percent moisturizing sweet almond oil and a plurality of avocados and whole aloe Vera plants weighing approximately 10 pounds of 100 percent pure fresh cut whole grown aloe Vera fresh plants. | 2013-08-29 |
20130224144 | SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS - Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 2013-08-29 |
20130224145 | COMPLEX HAVING TUMOR VACCINE EFFECT, AND USE THEREOF - The present invention provides a tumor cell-soluble TNF family member molecule complex containing a tumor cell and an isolated soluble TNF family member molecule, wherein the soluble TNF family member molecule is bound on a surface of the tumor cell such that it binds to a receptor of the TNF family member expressed on a surface of a cell other than the tumor cell, and stimulates the cell other than the tumor cell via the receptor, and a composition and a tumor vaccine, each containing the complex. | 2013-08-29 |
20130224146 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING - Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. | 2013-08-29 |
20130224147 | MACROCYCLIC SERINE PROTEASE INHIBITORS - Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2013-08-29 |
20130224148 | ACTIVATED LEUKOCYTE CONDITIONED SUPERNATANT AND USES FOR WOUND HEALING - Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds. | 2013-08-29 |
20130224149 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS - This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions. | 2013-08-29 |
20130224150 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES - The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival. | 2013-08-29 |
20130224151 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain - The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain. | 2013-08-29 |
20130224152 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections - Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity. | 2013-08-29 |
20130224153 | RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES - Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | 2013-08-29 |
20130224154 | RETARGETING OF RAT PARVOVIRUS H-1PV TO CANCER CELLS THROUGH GENETIC ENGINEERING OF ITS CAPSID - Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy. | 2013-08-29 |
20130224155 | COMPOSITIONS OF MICROBIOTA AND METHODS RELATED THERETO - Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed. | 2013-08-29 |
20130224156 | METHOD OF PRODUCING HUMAN RETINAL PIGMENT EPITHELIAL CELLS - The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell. | 2013-08-29 |
20130224157 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 2013-08-29 |
20130224158 | TISSUE REPAIR USING ALLOGENEIC DERMAL FIBROBLASTS - The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent tissue without the disadvantages that accompany the preparation and/or use of presently available materials such as autologous fibroblasts cells or collagen. | 2013-08-29 |
20130224159 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2013-08-29 |
20130224160 | Treatment of Vocal Cords with Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 2013-08-29 |
20130224161 | METHODS FOR ORGAN REGENERATION - A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject. | 2013-08-29 |
20130224162 | HUMAN NEURAL STEM CELLS EXPRESSING HUMAN CHOLINE ACETYLTRANSFERASE, AND USE THEREOF - The present invention relates to human neural stem cells (NSCs) transfected with a vector comprising a polynucleotide encoding human choline acetyltransferase (ChAT) and thereby stably expressing the human ChAT, a composition for treating Alzheimer disease or for improving a cognitive disorder comprising the human NSCs expressing a human ChAT. The present human NSCs genetically modified to express human ChAT, when transplanted into the brain of the animal AD model, successfully integrated into the host tissues and differentiated into the normal neuronal cells or glial cells. The instant genetically modified human NSCs stably express ChAT in the brain tissue of AD animal and thereby restore the acetylcholine level, and learning and memory function comparable to normal animal. The present genetically modified human NSCs expressing ChAT can be used for the treatment of AD as well as cognitive disorders due to other brain diseases and aging. | 2013-08-29 |
20130224163 | NEURONAL SPECIFIC TARGETING OF CAVEOLIN EXPRESSION TO RESTORE SYNAPTIC SIGNALING AND IMPROVE COGNITIVE FUNCTION IN THE NEURODEGENERATIVE BRAIN AND MOTOR FUNCTION IN SPINAL CORD - The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1. | 2013-08-29 |
20130224164 | Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use - Compositions and methods for inhibiting | 2013-08-29 |
20130224165 | DRINKING YOGHURT PREPARATIONS CONTAINING NON-REPLICATING PROBIOTIC MICRO-ORGANISMS - The present invention relates to the field of drinkable yoghurt compositions. In particular, the present invention provides drinkable yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic micro-organisms. | 2013-08-29 |
20130224166 | POWDERED CEREAL COMPOSITIONS COMPRISING NON-REPLICATING PROBIOTIC MICROORGANISMS - The present invention relates to the field of powdered cereal compositions to be reconstituted in milk, infant formula or water. In particular, the present invention relates to powdered cereal compositions to be administered to infants or young children. The powdered cereal compositions may be used to strengthen the immune system and/or to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to a powdered cereal composition comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms. | 2013-08-29 |
20130224167 | NON-REPLICATING PROBIOTIC BACTERIA AND PREVENTION OR TREATMENT OF INFECTIONS TO REDUCE ABSENCE FROM SCHOOL OR DAYCARE - The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from infections. The subject matter of the present inventions allows it to reduce absence from school or daycare. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of infections in children to reduce absence from school or daycare. | 2013-08-29 |
20130224168 | LACTOBACILLUS RHAMNOSUS AND WEIGHT CONTROL - The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embodiment of the present invention relates to the use of | 2013-08-29 |
20130224169 | COMPOSITION AND METHOD FOR RECOVERY FROM MILD TRAUMATIC BRAIN INJURY - A method and composition for reducing the recovery time for a human suffering from mild traumatic brain injury are provided. The composition is a mixture of component supplements that synergistically address the symptoms of the condition and the damage done by the injury. | 2013-08-29 |
20130224170 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET - A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: | 2013-08-29 |
20130224171 | AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE - 5-D-fructose dehydrogenase, optionally in combination with invertase and/or maltase and/or glucose isomerase, may be used to treat fructose intolerance. Other embodiments are also disclosed. | 2013-08-29 |
20130224172 | METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS - Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same. | 2013-08-29 |
20130224173 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-29 |
20130224174 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLYCYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-29 |
20130224175 | RECOMBINANT THERAPEUTIC GLYCINE N-ACYLTRANSFERASE - This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 2.1.3.13)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression piasmid; transforming the host with the expression piasmid to form an expression system; expressing the GLYAT gene in the expression system; and separating the expressed GLYAT from the expression system. | 2013-08-29 |
20130224176 | METHOD OF RESTORING THE INCRETIN EFFECT - The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof. | 2013-08-29 |
20130224177 | METHOD OF REGULATING FERTILIZING ABILITY USING CYCLIC ADP-RIBOSE AND CD38 - The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization. | 2013-08-29 |
20130224178 | Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 2013-08-29 |
20130224179 | PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH - The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. | 2013-08-29 |
20130224180 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 2013-08-29 |
20130224181 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS INCLUDING GALENICAL EXTRACT OR LACTOBACILLUS FERMENTATION THEREOF - The present invention relates to a pharmaceutical composition and health supplement for preventing or treating atopic dermatitis, the composition and supplement having as active ingredients extract of a galenical mixture including sophora root, licorice, lonicer aflower, Korean angelica root, Korean aralia root, saussurea root, seselos radix, zizyphus spinosi, Houttuynia cordata, forsythia fruit, lappa fruit, Epimedium koreanum Nakai, ginseng, lithospermum, oleoresin, cnidium, scorophulariae radix, and reynoutria, or lactobacillus fermentation of the galenical extract prepared by inoculating lactobacillus to the galenical extract and fermenting same. The galenical extract or the galenical extract fermentation of the present invention achieves reduced scratching, decreases clinical features of atopic symptoms such as erythema, itchiness and dry skin, edema and hematoma, erosion, and lichenification, and reduces IgE concentration in blood, which is related to exogenous atopic dermatitis, in laboratory animal models of atopic dermatitis, and is thereby, useful for preventing or treating atopic dermatitis. | 2013-08-29 |
20130224182 | BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE - The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G | 2013-08-29 |
20130224183 | FRACTION I-IV-1 PRECIPITATION OF IMMUNOGLOBINS FROM PLASMA - Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a method for fractionating pooled plasma is provided, the method comprising an initial low pH, high alcohol precipitation step. The present invention also provides pharmaceutical compositions of therapeutic blood proteins. | 2013-08-29 |